Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.0)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 6, June, p. 795–805

doi: 10.17219/acem/68990

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Hounsfield units from unenhanced 18F-FDG-PET/CT are useful in evaluating supradiaphragmatic lymph nodes in children and adolescents with classical Hodgkin’s lymphoma

Radosław Chaber1,A,B,C,D,F, Mateusz Łasecki2,A,B,C,D, Justyna Kwaśnicka3,B, Kornelia Łach1,C, Zbigniew Podgajny4,5,B,E, Cyprian Olchowy2,B, Urszula Zaleska-Dorobisz2,E,F

1 Department of Pediatric Oncology and Hematology, Faculty of Medicine, University of Rzeszów, Poland

2 Department of General and Pediatric Radiology, Wroclaw Medical University, Poland

3 Department of Pediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Poland

4 Affidea Center of Positron Emission Tomography and Computed Tomography, Wrocław, Poland

5 Department of Endocrinology and Isotopes Therapy, Military Institute of Medicine, Warszawa, Poland

Abstract

Background. The precise identification of the primarily-affected nodal regions in Hodgkin’s lymphoma
(HL) is essential in determining the stage of the disease and the intensity of chemotherapy and radiotherapy.
Objectives. The aim of this study was to use the degree of X-ray attenuation (XRA) in Hounsfield units
(HU) and the lymph node-to-muscle attenuation ratio (LN/M) in computed tomography (CT) unenhanced
imaging, routinely performed with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET),
to distinguish HL-affected supradiaphragmatic lymph nodes.
Material and methods. The study included 52 patients with classical HL treated according to the EuroNet-
PHL-C1 protocol. Patients received 2 chemotherapy cycles after 18F-FDG-PET/CT testing, followed
by re-examination. The lymph nodes were evaluated according to the Society for Pediatric Oncology and
Hematology’s GPOH-HD-2002 study and Lugano criteria as not-involved (NI-LN) and involved (I-LN).
Results. A significant difference (p < 0.001) was found in the XRA and LN/M values between NI-LN and
I-LN before treatment and after the 2 chemotherapy cycles. The optimal cut-off point for XRA (44.7 HU) and
LN/M (0.79) values distinguishing I-LN from NI-LN nodes was determined by receiver operating characteristic
(ROC) analysis. After 2 cycles of chemotherapy, higher XRA (p = 0.002) and LN/M (p = 0.001) values in the
group with inadequate early CTx response were found.
Conclusions. The use of XRA in HU and LN/M, together with the existing standard, can improve the qualification
of supradiaphragmatic lymph nodes in HL.
 

Key words

children, lymph nodes, Hodgkin’s lymphoma, positron-emission tomography

References (40)

  1. Ries LAG, Harkins D, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER web site, 2006.
  2. de Alarcon PA, Metzger M, Al-Rahawan MM. Pediatric Hodgkin lymphoma. Medscape News & Perspective. http://emedicine.medscape.com/article/987101-overview#a5. Accessed April 30, 2015.
  3. National Cancer Institute. PDQ® Childhood Hodgkin Lymphoma Treatment. National Cancer Institute, Bethesda. http://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq. Accessed February 3, 2016.
  4. van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007–1017.
  5. Chemaitilly W, Mertens AC, Mitby P, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006;91(5):1723–1728.
  6. Constine LS, Scott Gamis A, Gross TG, et al. PDQ® Childhood Hodgkin Lymphoma Treatment. National Cancer Institute, Bethesda. http://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq. Accessed March 31, 2016.
  7. Mauz-Körholz C, Hasenclever D, Dörffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: The GPOH-HD-2002 study. J Clin Oncol. 2010;28(23):3680–3686.
  8. Maraldo MV, Brodin NP, Aznar MC, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol. 2013;24(8):2113–2118.
  9. Raemaekers JM, Andre MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32(12):1188–1194.
  10. Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–862.
  11. EuroNet-Paediatric Hodgkin’s Lymphoma Group. First international Inter-Group Study for classical Hodgkin’s Lymphoma in Children and Adolescents EuroNet-PHL-C1. http://www.lymphome.de/Gruppen/GPOH-HD/Protokolle/EuroNet-PHL-C1_und_R1/Synopsis.pdf. Accessed September 10, 2007.
  12. EuroNet-Paediatric Hodgkin’s Lymphoma Group. Recommendations for the diagnostics and treatment of children and adolescents with a classical Hodgkin`s Lymphoma during the interimphase between the end of the EuroNet-PHL-C1 Study and the start of the EuroNet-PHL-C2 Study. https://www.skion.nl/workspace/uploads/EuroNet-PHL-Interim-Treatment-Guidelines-2012-12-3v0-2.pdf. Accessed January 30, 2013.
  13. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048–3058.
  14. Ries LAG, Melbert D, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
  15. Berg JW. The significance of axillary node levels in the study of breast carcinoma. Cancer. 1995;8:776–778.
  16. Som PM, Curtin HD, Mancuso AA. Imaging-based nodal classification for evaluation of neck metastatic adenopathy. Am J Roentgenol. 2000;174(3):837–844.
  17. El-Sherief AH, Lau CT, Wu CC, Drake RL, Abbott GF, Rice TW. International Association for the Study of Lung Cancer (IASLC) lymph node map: Radiologic review with CT illustration. Radiographics. 2014; 34(6):1680–1691.
  18. Papathanassiou D, Becker S, Amir R, Menéroux B, Liehnet JC. Respiratory motion artefact in the liver dome on FDG PET/CT: Comparison of attenuation correction with CT and a caesium external source. Eur J Nucl Med Mol Imaging. 2005;32(12):1422–1428.
  19. Pettinato C, Nanni C, Farsad M, et al. Artefacts of PET/CT images. Biomed Imaging Interv J. 2006;2(4):e60.
  20. Hanley JA, Hajian-Tilaki HO. Sampling variability of nonparametric estimates of the areas under the receiver operating characteristic curves: An update. Acad Radiol. 1997;4:49–58.
  21. Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TF. Hodgkin disease: Diagnostic value of FDG PET/CT after first-line therapy – is biopsy of FDG-avid lesions still needed? Radiology. 2007;244(1): 257–262.
  22. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica. 2001;86(3):266–273.
  23. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging – do we need contrast-enhanced CT? Radiology. 2004;232(3): 823–829.
  24. Pombo F, Rodriguez E, Caruncho MV, Villalva C, Crespo C. CT attenuation values and enhancing characteristics of thoracoabdominal lymphomatous adenopathies. J Comput Assist Tomogr. 1994;18(1):59–62.
  25. Flechsig P, Choyke P, Kratochwil C, et al. Increased X-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer. Diagn Interv Radiol. 2015;22(1):35–39.
  26. Yoon Kyung K, Kyung Soo L, Byung-Tae K, et al. Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country: Diagnostic efficacy in 674 patients. Cancer. 2007;109(6):1068–1077.
  27. Urata M, Kijima Y, Hirata M, et al. Computed tomography Hounsfield units can predict breast cancer metastasis to axillary lymph nodes. BMC Cancer. 2014;14:730.
  28. Kim SA, Lee KN, Kang EJ, Kim DW, Hong SH. Hounsfield units upon PET/CT are useful in evaluating metastatic regional lymph nodes in patients with oesophageal squamous cell carcinoma. Br J Radiol. 2012;85(1013):606–612.
  29. Follows GA, Ardeshna KM, Barrington SF, et al. Guidelines for the first line management of classical Hodgkin lymphoma. Br J Haematol. 2014;166(1):34–49.
  30. Dillman JR, Strouse PJ, Ellis JH, Cohan RH, Jan SC. Incidence and severity of acute allergic-like reactions to i.v. nonionic iodinated contrast material in children. AJR Am J Roentgenol. 2007;188(6):1643–1647.
  31. Zo’o M, Hoermann M, Balassy C, et al. Renal safety in pediatric imaging: Randomized, double-blind phase IV clinical trial of Iobitridol 300 versus Iodixanol 270 in multidetector CT. Pediatr Radiol. 2011;41(11): 1393–1400.
  32. Amato E, Salamone I, Naso S, Bottari A, Gaetand M, Blandino A. Can contrast media increase organ doses in CT examinations? A clinical study. AJR Am J Roentgenol. 2013;200(6):1288–1293.
  33. Birnbaum BA, Hindman N, Lee J, Babb JS. Renal cyst pseudoenhancement: Influence of multidetector CT reconstruction algorithm and scanner type in Phantom Model 1. Radiology. 2007;244(3):767–775.
  34. Boas FE, Fleischmann D. CT artifacts: Causes and reduction techniques. Imaging Med. 2012;4(2):229–240.
  35. Morrill SM, Langer ML, Lane RG, Rosen II. Tissue heterogeneity effects in treatment plan optimization. Int J Radiat Oncol Biol Phys. 1994;30(3): 699–706.
  36. Burridge NA, Rowbottom CG, Bur PA. Effect of contrast-enhanced CT scans on heterogeneity corrected dose computations in the lung. J Appl Clin Med Phys. 2006;7(4):1–12.
  37. Elmore SA. Histopathology of the lymph nodes. Toxicol Pathol. 2006; 34(5):425–454.
  38. Tan BB, Flaherty KR, Kazerooni EA, Iannettoni MD. The solitary pulmonary nodule. Chest. 2003;123:89S–96S.
  39. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. JAMA. 2001;285:914–924.
  40. Bui AT, Taira RK. Medical data visualization: Toward integrated clinical workstations. In: Bui AT, Taira RK, eds. Medical Imaging Informatics. New York, NY: Springer Science & Business Media; 2010:139–193.
© Wroclaw Medical University